ATYPICAL UREMIC HEMOLYTIC SYNDROME (SHUA) AFTER KIDNEY TRANSPLANTATION

• Autor(a) principal: Barbosa, Thamara Cardoso
• Data de Publicação: 2020
• Outros Autores: Caixeta, Mariellen da Silva, Santos, Walquiria Lene dos, Álvares, Alice da Cunha Morales
• Tipo de documento: Artigo
• Idioma: por; eng
• Título da fonte: Revista JRG de Estudos Acadêmicos
• Texto Completo: http://revistajrg.com/index.php/jrg/article/view/32
• topic: Síndrome Hemolítica Urêmica Atípica. Microangiopatia trombótica. Eculizumab.; Atypical Hemolytic Uremic Syndrome. Thrombotic microangiopathy. Eculizumab.

Hemolytic uremic syndrome (HUS) is a disease that belongs to the group of thrombotic microangiopathies1, a serious disease defined by the triad of microangiopathic hemolytic anemia, thrombocytopenia and acute kidney injury. It is divided into two subtypes, the typical SHU and the atypical SHU (SHUa). This division is based on the clinical presentation and, mainly, on the causes of the syndrome. The aim of this study was to identify cases of recurrence of Atypical Hemolytic Uremic Syndrome after Kidney Transplantation. This is an integrative review of a qualitative approach, carried out from August 2019 to June 2020. References were sought such as: Scientific Eletronic Library Online, Brazilian Journal of Nephrology, Ministry of Health, MEDLINE and BDENF, where they were researched and studied 22, of which 6 were more relevant to the development of this work. The results of the study demonstrate that although it is considered a serious disease, there are few studies carried out on HUSA, and with a long period of time between publications, however the recurrence of HUSA after renal transplantation requiring drug treatment with Eculizumab is concluded. throughout life.